Conference Scene: Progress with promising human antibodies

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 257-261

  Larrick, James W ^a  

^a Panorama Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTIRHEUMATIC AGENT; BRENTUXIMAB VEDOTIN; CETUXIMAB; EPITOPE; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; IMMUNOGLOBULIN G1; INTERFERON RECEPTOR; KLOTHO PROTEIN; LYMPHOTOXIN; MONOCLAL ANTIBODY KBSA301; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AFM13; MONOCLONAL ANTIBODY CLAUDIN1; MONOCLONAL ANTIBODY FCRN; MONOCLONAL ANTIBODY GNBAC1; MONOCLONAL ANTIBODY SYMOO4; PRITUMUMAB; PROBODIES; PROTEINASE; RECOMBINANT ANTIBODY; SMAD2 PROTEIN; SMAD4 PROTEIN; SYM 400; TANDABS; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN; ZALUTUMUMAB;

ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN CANCER; BREAST CANCER; CALCIUM METABOLISM; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COLON CANCER; CONFERENCE PAPER; DENGUE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG MARKETING; ECONOMIC DEVELOPMENT; GALLBLADDER CANCER; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLOMERULONEPHRITIS; HEAD AND NECK CANCER; HEPATITIS C; HODGKIN DISEASE; HUMAN; HYBRIDOMA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; LISTERIOSIS; LUNG CANCER; MEDICAL EDUCATION; MELANOMA; METABOLIC REGULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS CANCER; PHOCOMELIA; PHOSPHATE METABOLISM; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCIENTIFIC LITERATURE; SMALLPOX; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; THERMOSTABILITY; THYROID CANCER; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; FRANCE; HUMANS; PERIODICALS AS TOPIC;

EID: 84858307839     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.5     Document Type: Conference Paper

References (7)

1. Kokunai T. Anti-TA226 human monoclonal antibody (ACA-11) against glioma. [Article in Japanese] Nihon Rinsho 60(1), 100-106 (2002).
2. Iwakoshi T, Kobayashi T, Kida Y, et al. Results of an immunotherapy using human monoclonal antibody for gliomas: findings in ten cases. Jap. J. Neurosurg. 5(4), 266-272 (1996). (Pubitemid 26287012)
3. Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M. Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice. Infect. Immun. 76(7), 2958-2965 (2008).
4. Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233(1), 34-54 (2010).
5. Davis JH, Aperlo C, Li Y, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23(4), 195-202 (2010).
6. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 15(7), 766-773 (2009).
7. US NIH clinical trials. http://clinicaltrials.gov/